Bioventus Board of Managers Appoints Bill Hawkins Chairman
Bioventus Board of Managers Appoints Bill Hawkins Chairman
DURHAM, NC – January 11, 2016 – Bioventus, a global leader in orthobiologic solutions, today announced the appointment of Bill Hawkins, retired Chairman and CEO of Medtronic and currently Lead Director of Immucor, as its new Chairman of the company’s Board of Managers. Dan Lemaitre, who has served as Chairman since the inception of Bioventus in 2012, has decided to leave the company’s Board.
“I want to thank Dan Lemaitre for his vision, energy, sage counsel and leadership of our Board of Managers since Bioventus became a standalone company in 2012. His contributions to our early successes were numerous,” said Tony Bihl, CEO of Bioventus. “As we move into 2016, we are excited to have Bill Hawkins join us to lead our Board as Chairman. As former CEO of one of the most successful global medical device companies, Bill brings very strong experience in orthobiologics, including BMP, and we look forward to working with him and our Board to continue to grow Bioventus in this space.”
From October 2011 to July 2015, Hawkins served as President and CEO of Immucor, a leading provider of transfusion and transplantation diagnostic products worldwide. Prior to that, he served as Chairman and CEO of Medtronic. Previously, he served as President and CEO of Novoste Corp. Hawkins has also held senior leadership positions at American Home Products, Johnson & Johnson, Guidant Corp., and Eli Lilly and Company.
Hawkins received his bachelor's degree in electrical and biomedical engineering from Duke University in 1976, where he also conducted medical research in pathology. He then went on to earn an MBA from the Darden School of Business, University of Virginia, in 1982. He is also active on public and private boards as well as non for profit boards.
About Bioventus
Bioventus LLC is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Bioventus has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.
Media Contact:
Thomas Hill [email protected]
Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
Bioventus Launches DUROLANE for Osteoarthritis Patients in Taiwan
Bioventus Launches DUROLANE® for Osteoarthritis Patients in Taiwan
HOOFDDORP, THE NETHERLANDS – January 4, 2016 – Bioventus, a leader in orthobiologic solutions, today announced its entry into the patient care market in Taiwan with the launch of DUROLANE®, a single-injection joint-fluid osteoarthritis (OA) treatment based on a natural, safe and proven technology process called NASHA® which yields stabilized hyaluronic acid (HA).
Hyaluronic acid is a naturally occurring molecule that provides the lubrication and cushioning in a normal joint. In Taiwan, DUROLANE is indicated for the treatment of mild to moderate (OA) of the knee.
“The combination of a leading OA solution like DUROLANE and Taiwan’s robust economy gives Bioventus a terrific opportunity to establish itself and grow in this market,” said Tony Bihl, CEO, Bioventus. “Orthobiologic solutions from Bioventus are now available in six countries in the Asia Pacific region and we plan to build on this as we continue our international expansion.”
“In Taiwan, Bioventus will be working with Eulogiums, a sales and marketing leader with more than 20 years of experience in orthopaedics,” said Isabelle Levy-Unger, Managing Director International, for Canada, Latin America and Asia Pacific, Bioventus. “The company’s market coverage, relationships with key opinion leaders, along with its keen understanding of markets and trends made it the natural choice to help us introduce DUROLANE to patients with knee OA,” she added.
"We believe that only knee OA products with superior quality can withstand in the competitive market in Taiwan and we have confidence that DUROLANE is the one," said Kenny Liu, CEO, Eulogiums Co Ltd.
Bioventus will continue to work with the current network of distributors carrying the BioStructures product portfolio and expand that sales footprint to bring these solutions to more surgeons and hospitals throughout the US.
DUROLANE is available in Taiwan now and more information about the product can be found at www.durolane.com.
About Bioventus
Bioventus LLC is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. Bioventus has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.
Media Contacts:
Thomas Hill [email protected] or Berdine Vonk +31 (0)23 554 88 14 [email protected]
DUROLANE - Indications
For the symptomatic treatment of mild to moderate knee osteoarthritis.
There are no known contraindications. You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Risks can include transient pain, swelling and/or stiffness at the injection site. Clinical effectiveness has been demonstrated out to six months but results may vary depending on various patient factors.
Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC. DUROLANE and NASHA are registered trademarks of Galderma S.A.
